Literature DB >> 29166232

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.

Bruce Neal1,2, Vlado Perkovic1, David R Matthews3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29166232     DOI： 10.1056/NEJMc1712572

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  77 in total

Review 1.  Risk of fracture with dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in real-world use: systematic review and meta-analysis of observational studies.

Authors:  K Hidayat; X Du; B-M Shi
Journal:  Osteoporos Int       Date:  2019-05-27       Impact factor: 4.507

2.  Safety of Liraglutide in Type 2 Diabetes and Chronic Kidney Disease.

Authors:  Johannes F E Mann; Vivian A Fonseca; Neil R Poulter; Itamar Raz; Thomas Idorn; Søren Rasmussen; Bernt Johan von Scholten; Ofri Mosenzon
Journal:  Clin J Am Soc Nephrol       Date:  2020-03-04       Impact factor: 8.237

3.  SGLT2 inhibition reprograms systemic metabolism via FGF21-dependent and -independent mechanisms.

Authors:  Soravis Osataphan; Chiara Macchi; Garima Singhal; Jeremy Chimene-Weiss; Vicencia Sales; Chisayo Kozuka; Jonathan M Dreyfuss; Hui Pan; Yanin Tangcharoenpaisan; Jordan Morningstar; Robert Gerszten; Mary-Elizabeth Patti
Journal:  JCI Insight       Date:  2019-03-07

Review 4.  Bridging the Gap for Patients with Diabetes and Cardiovascular Disease Through Cardiometabolic Collaboration.

Authors:  Lee-Shing Chang; Muthiah Vaduganathan; Jorge Plutzky; Vanita R Aroda
Journal:  Curr Diab Rep       Date:  2019-12-04       Impact factor: 4.810

Review 5.  Diabetes, Lipids, and CV Risk.

Authors:  Jan Škrha
Journal:  Curr Atheroscler Rep       Date:  2021-01-19       Impact factor: 5.113

Review 6.  Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Non-Diabetic Chronic Kidney Disease.

Authors:  Akira Mima
Journal:  Adv Ther       Date:  2021-04-16       Impact factor: 3.845

7.  Inhibition of sodium-glucose cotransporter-2 preserves cardiac function during regional myocardial ischemia independent of alterations in myocardial substrate utilization.

Authors:  Hana E Baker; Alexander M Kiel; Samuel T Luebbe; Blake R Simon; Conner C Earl; Ajit Regmi; William C Roell; Kieren J Mather; Johnathan D Tune; Adam G Goodwill
Journal:  Basic Res Cardiol       Date:  2019-04-19       Impact factor: 17.165

8.  Mechanism of Increased LDL (Low-Density Lipoprotein) and Decreased Triglycerides With SGLT2 (Sodium-Glucose Cotransporter 2) Inhibition.

Authors:  Debapriya Basu; Lesley-Ann Huggins; Diego Scerbo; Joseph Obunike; Adam E Mullick; Paul L Rothenberg; Nicholas A Di Prospero; Robert H Eckel; Ira J Goldberg
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-09       Impact factor: 8.311

Review 9.  A Role for SGLT-2 Inhibitors in Treating Non-diabetic Chronic Kidney Disease.

Authors:  Lucia Del Vecchio; Angelo Beretta; Carlo Jovane; Silvia Peiti; Simonetta Genovesi
Journal:  Drugs       Date:  2021-08-07       Impact factor: 9.546

Review 10.  Sodium-Glucose Cotransporter-2 Inhibitors in Vascular Biology: Cellular and Molecular Mechanisms.

Authors:  Lei Xiao; Xin Nie; Yanyan Cheng; Nanping Wang
Journal:  Cardiovasc Drugs Ther       Date:  2021-07-17       Impact factor: 3.727
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.